Salute e Benessere
BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT
The Company intends to use the proceeds of the Private Placement for general working capital purposes, including enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., which was purchased from IMV USA ("IMV") on February 16, 2024 .
No finder's fees were paid in connection with the Fifth Tranche. All securities issued pursuant to the Fifth Tranche are subject to a statutory hold period expiring February 5, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation.
In addition, the Company announces the issuance of 1,532,500 Shares at a deemed price of $0.05 per Share to settle an aggregate of $76,625 in debt owed to a consultant (the " "). All securities issued pursuant to the Debt Settlement are subject to a statutory hold period expiring February 2, 2025 , being the date that is four months and one day from the date of issuance in accordance with applicable securities legislation.
The securities described herein have not been, and will not be, registered under the , as amended (the " "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States .
BioVaxys Technology Corp. ( www.biovaxys.com ) , a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
Signed " "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
View original content: https://www.prnewswire.co.uk/news-releases/biovaxys-announces-closing-of-fifth-tranche-of-private-placement-302268125.html